Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition

Pharmacy Times® will be live in Orlando, Florida, for coverage of the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, which takes place December 6 through 9 at the Orange County Convention Center.

Each year at the ASH Annual Meeting and Exposition, thousands of attendees come together to explore the latest developments shaping hematology. The event features an extensive slate of sessions and a wide range of abstracts showcasing new therapies, emerging data, and key scientific insights. Pharmacy Times will be on site reporting on late-breaking abstracts, clinical trial findings, and new research in multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, hemophilia, and sickle cell disease, along with updates on advances in minimal residual disease (MRD) testing, bispecific antibodies, and CAR T-cell therapies.

Keep an eye on PharmacyTimes.com and our social media platforms for exclusive session coverage and expert insights, with highlights that include:

• An exclusive interview with Alfred Chung, MD, a hematologist-oncologist and professor at the University of California, San Francisco, discussing data from the AURIGA (NCT03901963) trial investigating minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab (Darzalex; Johnson & Johnson) plus lenalidomide (Revlimid; Bristol Myers Squibb) versus lenalidomide alone as maintenance therapy.
• A “Special Symposium on the Basic Science of Hemostasis and Thrombosis,” which will examine how coagulation, platelet activity, and fibrinolysis work in concert to drive healing, and how disturbances in these pathways can fuel organ injury and thrombotic disease. Speakers will explore the molecular timing that determines whether wounds regenerate or scar, the emerging role of von Willebrand factor in hemolysis-driven liver pathology, and new insights into how lipoprotein(a) may influence thrombin generation, fibrin structure, and clot stability across bleeding and thrombotic conditions.
• An interview with Saad Usmani, MD, MBA, FACP, FASCO, a hematologist-oncologist at Memorial Sloan Kettering Cancer Center, discussing the efficacy and safety of talquetamab (Talvey; Johnson & Johnson) plus teclistamab (Tecvayli; Johnson & Johnson) in patients with relapsed/refractory multiple myeloma and extramedullary disease.
• Discussions on the real-world challenges of helping patients navigate newly approved gene therapies for sickle cell disease. A panel of hematologists and lived-experience experts will outline how clinicians can identify appropriate candidates, prepare patients for the intensive treatment process, manage complications during therapy, and support long-term recovery and continuity of care.
• An interview with Binod Dhakal, MD, of the Medical College of Wisconsin, reviewing data from the phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. These new data suggest that carefully selected bridging therapy corresponds with improved outcomes after treatment with ciltacabtagene autoleucel.

Coverage will continue throughout the duration of the conference, so follow our website and social media for the latest updates from the ASH Annual Meeting and Exposition.